Compare iShares MSCI China ETF (MCHI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Mesoblast Limited — how do they compare? iShares MSCI China ETF trades at $52.55 (market cap $5.94B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: iShares MSCI China ETF is far larger — about 3.4× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 1,575,471). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and Mesoblast Limited for 15 Days on average.
| MCHI | MESO | |
|---|---|---|
Market Cap | $5.94B | $1.75B |
Volume | 1,575,471 | 239,027 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $20.96 |
52-Week Low | $50.48 | $13.19 |
Typical Hold Time | 63 Days | 15 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $52.55, up 1.76% today, but technical indicators show a bearish trend with moving averages signaling strong selling pressure. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights potential trade tensions ahead of the Trump-Xi summit, though corporate profits surged 26% in Q2 according to Zacks Investment Research (2026-09-08).
The outlook remains cautious due to China's macroeconomic pressures and global trade risks. Investment opportunity exists in MCHI's significant discount to historical valuations versus US indices, but risks include potential export controls and protectionism. The ETF's financial sector benefits from China's steepening yield curve, supporting bank and insurance holdings.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
